

SPONSORED
Today's podcast features a discussion with experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, from the 66th ASH Annual Meeting and Exposition. They share their key highlights in amyloidosis from the meeting, including updates from the ANDROMEDA trial (NCT03201965), the risk stratification of patients with light chain (AL) amyloidosis, the value of measurable residual disease (MRD), and potential advances with CAR T-cell therapy in this disease setting.
200 episodes
Today's podcast features a discussion with experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, from the 66th ASH Annual Meeting and Exposition. They share their key highlights in amyloidosis from the meeting, including updates from the ANDROMEDA trial (NCT03201965), the risk stratification of patients with light chain (AL) amyloidosis, the value of measurable residual disease (MRD), and potential advances with CAR T-cell therapy in this disease setting.
200 episodes
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.